Cited by 119Acute Myeloid Leukemia ResearchCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 142 of the 145 references it cites were found in a registry or an index.

Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity

Open access

Lamble, Adam J., Lind, Evan F.·2018·Frontiers in Oncology

DOI 10.3389/fonc.2018.00213PMC PMC6008423

Open this paper in CoChat — free account Open PDF

Abstract

Immunotherapies, such as chimeric antigen receptor T cells, bispecific antibodies, and immune checkpoint inhibitors, have emerged as promising modalities in multiple hematologic malignancies. Despite the excitement surrounding immunotherapy, it is currently not possible to predict which patients will respond. Within solid tumors, the status of the immune microenvironment provides valuable insight regarding potential responses to immune therapies. Much less is known about the immune microenvironment within hematologic malignancies but the characteristics of this environment are likely to serve a similar predictive role. Acute myeloid leukemia (AML) is the most common hematologic malignancy in adults, and only 25% of patients are alive 5 years following their diagnosis. There is evidence that manipulation of the immune microenvironment by leukemia cells may play a role in promoting therapy resistance and disease relapse. In addition, it has long been documented that through modulation of the immune system following allogeneic bone marrow transplant, AML can be cured, even in patients with the highest risk disease. These concepts, along with the poor prognosis associated with this disease, have encouraged many groups to start exploring the utility of novel immune therapies in AML. While the implementation of these therapies into clinical trials for AML has been supported by preclinical rationale, many questions still exist surrounding their efficacy, tolerability, and the overall optimal approach. In this review, we discuss what is known about the immune microenvironment within AML with a specific focus on T cells and checkpoints, along with their implications for immune therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fonc.2018.00213

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 3×
“Curr Opin Immunol (2007) 19(3):309–14.”
Influential
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Rp, G., Pm, S., Goldman, J. M., Kersey, J., Kolb, H., Rimm, A., Ringdén, O. T. H., Rozmán, C., & SPECK, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,769
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680

Show all 145 references

Sorted by citations

Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia
Tang, L., Wu, J., Li, C.-G., Jiang, H., Xu, M., Du, M., Yin, Z., Mei, H., & Hu, Y. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3003 · Cited by 140
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy
Abbas, H. A., Hao, D., Tomczak, K. J., Barrodia, P., Im, J. S., Reville, P. K., Alaniz, Z., Wang, W., Wang, R., Wang, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26282-z · Cited by 130
Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia
Lamble, A. J., Kosaka, Y., Laderas, T., Maffit, A., Kaempf, A. J., Brady, L., Wang, W., Long, N., Saultz, J. N., Mori, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916206117 · Cited by 98
Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy
Khaldoyanidi, S. K., Nagorsen, D., Stein, A. S., Ossenkoppele, G. J., & Subklewe, M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00475 · Cited by 108
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets
Stahl, M. F., & Goldberg, A. D. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0781-7 · Cited by 102
TIM-3 pathway dysregulation and targeting in cancer
Zeidan, A. M., Komrokji, R. S., & Brunner, A. M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1865814 · Cited by 92
Inflammatory bone marrow microenvironment
Leimkühler, N. B., & Schneider, R. K. (2019) · Hematology · doi:10.1182/hematology.2019000045 · Cited by 82
Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways
Taghiloo, S., & Asgarian‐Omran, H. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103164 · Cited by 85
Integrated cancer tissue engineering models for precision medicine
Bregenzer, M. E., Horst, E. N., Mehta, P., Novak, C. M., Raghavan, S. A., Snyder, C. S., & Mehta, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216564 · Cited by 84
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Nie, Y., Lu, W., Chen, D., Tu, H., Guo, Z., Zhou, X., Li, M., Tu, S., & Li, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00197-1 · Cited by 85
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
Ladikou, E. E., Sivaloganathan, H., Pepper, A. G. S., & Chevassut, T. J. T. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0885-0 · Cited by 73
Alterations of T-cell-mediated immunity in acute myeloid leukemia
Li, Z., Philip, M., & Ferrell, P. B. (2020) · Oncogene · doi:10.1038/s41388-020-1239-y · Cited by 68
T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword
Vlachonikola, E., Σταματόπουλος, Κ., & Chatzidimitriou, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612244 · Cited by 65
A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia
Saxena, K., Herbrich, S. M., Pemmaraju, N., Kadia, T. M., Dinardo, C. D., Borthakur, G. M., Pierce, S. A., Jabbour, E. J., Wang, S. A., Bueso-Ramos, C., et al. (2021) · Cancer · doi:10.1002/cncr.33690 · Cited by 62
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia
Restelli, C., Ruella, M., Paruzzo, L., Tarella, C., Pelicci, P. G., & Colombo, E. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0202 · Cited by 58
Bispecific Antibodies in Hematological Malignancies: A Scoping Review
Omer, M. H., Shafqat, A., Ahmad, O., AlKattan, K. M., Yaqinuddin, A., & Damlaj, M. (2023) · Cancers · doi:10.3390/cancers15184550 · Cited by 60
Targeting the innate immune system in pediatric and adult AML
Perzolli, A., Koedijk, J. B., Zwaan, C. M., & Heidenreich, O. T. (2024) · Leukemia · doi:10.1038/s41375-024-02217-7 · Cited by 55
Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Wong, K. K., Hassan, R., & Yaacob, N. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.624742 · Cited by 52
Acute myeloid leukaemia and the immune system: implications for immunotherapy
Barrett, A. J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16310 · Cited by 49
Identification of prognostic genes in the acute myeloid leukemia microenvironment
Huang, S., Zhang, B., Fan, W., Zhao, Q., Yang, L., Xin, W., & Fu, D. (2019) · Aging · doi:10.18632/aging.102477 · Cited by 48
Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials
Xu, Y., Li, P., Liu, Y., Xin, D., Lei, W., Liang, A., Han, W., & Qian, W. (2022) · 癌症：英文版 · doi:10.1002/cac2.12313 · Cited by 47
The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy
Mendez, L., Posey, R. R., & Pandolfi, P. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01162 · Cited by 46
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
Bewersdorf, J. P., Shallis, R. M., & Zeidan, A. M. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100709 · Cited by 44
Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?
Ciciarello, M., Corradi, G., Forte, D., Cavo, M., & Curti, A. (2021) · Cancers · doi:10.3390/cancers13215319 · Cited by 45
4-1BBL–containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells
Swatler, J., Turos-Korgul, L., Brewińska‐Olchowik, M., Biasi, S. D., Dudka, W., Le, B. V., Kominek, A., Cyranowski, S., Pilanc, P., Mohammadi, E., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006195 · Cited by 43
Opportunities for immunotherapy in childhood acute myeloid leukemia
Lamble, A. J., & Tasian, S. K. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000357 · Cited by 39
Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern
Dozzo, A., Galvin, A., Shin, J., Scalia, S., O’Driscoll, C. M., & Ryan, K. B. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01189-4 · Cited by 43
Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias
Swatler, J., Turos-Korgul, L., Kozłowska, E., & Piwocka, K. (2021) · Cancers · doi:10.3390/cancers13061203 · Cited by 38
BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells
Romine, K. A., MacPherson, K., Cho, H.-J., Kosaka, Y., Flynn, P., Byrd, K., Coy, J. L., Newman, M., Pandita, R., Loo, C. P., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01808-0 · Cited by 35
Increased frequency of TIGIT + CD73-CD8 + T cells with a TOX + TCF-1low profile in patients with newly diagnosed and relapsed AML
Brauneck, F., Haag, F., Woost, R., Wildner, N. H., Tolosa, E., Rissiek, A., Vohwinkel, G., Wellbrock, J., Bokemeyer, C., Wiesch, J. S. Z., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1930391 · Cited by 34
The Role of T Cell Immunotherapy in Acute Myeloid Leukemia
Hao, F., Sholy, C., Wang, C., Cao, M., & Kang, X. (2021) · Cells · doi:10.3390/cells10123376 · Cited by 34
CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them
Vanhooren, J., Dobbelaere, R., Derpoorter, C., Deneweth, L., Camp, L. V., Uyttebroeck, A., Moerloose, B. D., & Lammens, T. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000937 · Cited by 34
RETRACTED ARTICLE: Acute myeloid leukemia-derived exosomes deliver miR-24-3p to hinder the T-cell immune response through DENN/MADD targeting in the NF-κB signaling pathways
Otmani, K., Rouas, R., Lagneaux, L., Krayem, M., Duvillier, H., Berehab, M., & Lewalle, P. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01259-1 · Cited by 33
Retracted
Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies
Rao, A., Agrawal, A., Borthakur, G. M., Battula, V. L., & Maiti, A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007981 · Cited by 33
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1589374 · Cited by 35
An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy
Wang, Y., Cai, Y., Herold, T., Nie, R., Zhang, Y., Gale, R. P., Metzeler, K. H., Zeng, Y., Wang, S., Pan, X.-Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3417 · Cited by 30
Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough?
Ganesan, S., Mathews, V., & Vyas, N. (2021) · International Journal of Cancer · doi:10.1002/ijc.33908 · Cited by 29
m6A-related lncRNAs predict prognosis and indicate immune microenvironment in acute myeloid leukemia
Zhong, F., Yao, F., Cheng, Y., Liu, J., Zhang, N., Li, S., Li, M., Huang, B., & Wang, X. (2022) · Scientific Reports · doi:10.1038/s41598-022-05797-5 · Cited by 30
Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment
Kogan, A. A., Lapidus, R. G., Baer, M. R., & Rassool, F. V. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2018.12.005 · Cited by 28
Identification of an Immune-Related Gene Signature Based on Immunogenomic Landscape Analysis to Predict the Prognosis of Adult Acute Myeloid Leukemia Patients
Zhu, R., Tao, H., Lin, W., Tang, L. V., & Hu, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574939 · Cited by 29
Expression of immune check point gene TIM‑3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome
Kamal, A. M., Nabih, N. A., Elleboudy, N. S., & Radwan, S. M. (2021) · Oncology Letters · doi:10.3892/ol.2021.12587 · Cited by 28
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment
Serroukh, Y. I. M., Hébert, J., Busque, L., Mercier, F., Rudd, C. E., Assouline, S. E., Lachance, S., & Delisle, J. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100991 · Cited by 30
Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
Aureli, A., Marziani, B., Sconocchia, T., Principe, M. I. D., Buzzatti, E., Pasqualone, G., Venditti, A., & Sconocchia, G. (2021) · Cancers · doi:10.3390/cancers13246246 · Cited by 25
Diversity, localization, and (patho)physiology of mature lymphocyte populations in the bone marrow
Schürch, C. M., Caraccio, C., & Nolte, M. A. (2021) · Blood · doi:10.1182/blood.2020007592 · Cited by 26
Antiproliferative and Immunoregulatory Effects of Azelaic Acid Against Acute Myeloid Leukemia via the Activation of Notch Signaling Pathway
Dongdong, Z., Jin, Y., Yang, T., Yang, Q., Wu, B., Chen, Y., Luo, Z., Li, L., Liu, Y., Xu, A., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01396 · Cited by 23
Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics
Roussel, X., Daguindau, É., Berceanu, A., Desbrosses, Y., Warda, W., Rocha, M. N. D., Trad, R., Deconinck, É., Deschamps, M., & Ferrand, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.599933 · Cited by 24
Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Barakos, G. P., & Hatzimichael, E. C. (2022) · Diseases · doi:10.3390/diseases10020033 · Cited by 24
A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia
Aru, B., Pehlivanoğlu, C., Dal, Z., DERELI-CALISKAN, N. N., Gürlü, E., & Demirel, G. Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1108200 · Cited by 24
STING-activating cyclic dinucleotide-manganese nanoparticles evoke robust immunity against acute myeloid leukemia
Aikins, M. E., Sun, X., Dobson, H. E., Zhou, X., Xu, Y., Lei, Y. L., & Moon, J. J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.022 · Cited by 21
Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
Epperly, R., Gottschalk, S. M., & Velasquez, M. P. (2020) · Children · doi:10.3390/children7020014 · Cited by 21
Pediatric leukemia: Moving toward more accurate models
Milan, T., Canaj, H., Villeneuve, C., Ghosh, A., Barabé, F., Cellot, S., & Wilhelm, B. T. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.05.003 · Cited by 22
Impact of Bone Marrow miR-21 Expression on Acute Myeloid Leukemia T Lymphocyte Fragility and Dysfunction
Agha, D. M., Rouas, R., Najar, M., Bouhtit, F., Fayyad‐Kazan, H., Lagneaux, L., Bron, D., Meuleman, N., Lewalle, P., & Merimi, M. (2020) · Cells · doi:10.3390/cells9092053 · Cited by 19
Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia
Gurska, L. M., & Gritsman, K. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.39 · Cited by 17
Acute myeloid leukemia–induced T-cell suppression can be reversed by inhibition of the MAPK pathway
Moshofsky, K. B., Cho, H. J., Wu, G., Romine, K. A., Newman, M., Kosaka, Y., McWeeney, S. K., & Lind, E. F. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000574 · Cited by 18
Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward
Koedijk, J. B., van der Werf, I. M., Calkoen, F., Nierkens, S., Kaspers, G. J. L., Zwaan, C. M., & Heidenreich, O. T. (2021) · Cancers · doi:10.3390/cancers13174364 · Cited by 16
The potential role of the thymus in immunotherapies for acute myeloid leukemia
Hino, C., Xu, Y., Xiao, J., Baylink, D. J., Reeves, M. E., & Cao, H. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1102517 · Cited by 18
EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
Masamoto, Y., Chiba, A., Mizuno, H., Hino, T., Hayashida, H., Sato, T., Bando, M., Shirahige, K., & Kurokawa, M. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008018 · Cited by 17
Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal
BERNASCONI, P. P., & Borsani, O. (2021) · Cancers · doi:10.3390/cancers13133170 · Cited by 16
Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia
Forghieri, F., Riva, G., Lagreca, I., Barozzi, P., Bettelli, F., Paolini, A., Nasillo, V., Lusenti, B., Pioli, V., Giusti, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179159 · Cited by 15
Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity
de Araújo, N. D., Magalhães-Gama, F., Barros, M. D. S., Pereira-Ribeiro, T. L., Alves-Hanna, F. S., Xábregas, L. A., Tarragô, A. M., Malheiro, A., & Costa, A. G. (2021) · Journal of Immunology Research · doi:10.1155/2021/6633824 · Cited by 17
HDAC1 regulates the chemosensitivity of laryngeal carcinoma cells via modulation of interleukin-8 expression
Ding, S., Tang, Z., Jiang, Y., Luo, P., Qing, B., Wei, Y., Zhang, S., & Tang, R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173923 · Cited by 14
Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche
Bauer, M., Vaxevanis, C., Bethmann, D., Massa, C., Pazaitis, N., Wickenhauser, C., & Seliger, B. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.055 · Cited by 13
Combination therapy of acute myeloid leukemia by dual PI3K/mTOR inhibitor BEZ235 and TLR-7/8 agonist R848 in murine model
Taghiloo, S., Ajami, A., Alizadeh‐Navaei, R., & Asgarian‐Omran, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111211 · Cited by 12
Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay
Kaleka, G., & Schiller, G. J. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106732 · Cited by 11
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
Bewersdorf, J. P., & Zeidan, A. M. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101222 · Cited by 10
Landscape of T Cells in NK-AML(M4/M5) Revealed by Single-Cell Sequencing
Wu, W., Liang, X., Li, H., Huang, X., Wan, C., Xie, Q., & Liu, Z. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5a0721-396rr · Cited by 11
Immune control in acute myeloid leukemia
Straube, J., Janardhanan, Y., Haldar, R., & Bywater, M. J. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104256 · Cited by 11
The role of Colchicine on actin polymerization dynamics: as a potent anti-angiogenic factor
Pathak, S., Gupta, R., Parkar, H., Joshi, N., Nagotu, S., & Kale, A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1965911 · Cited by 10
Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation
Vaidya, A. B., Doherty, E., Wu, X., Huang, S., Hebbar, N., Thanekar, U., Bonifant, C. L., Cheng, C., Gottschalk, S. M., & Velasquez, M. P. (2022) · Haematologica · doi:10.3324/haematol.2021.279301 · Cited by 10
JMJD3-regulated expression of IL-6 is involved in the proliferation and chemosensitivity of acute myeloid leukemia cells
Xu, X., Ye, Y., Wang, X., Lü, B., Guo, Z., & Wu, S. (2020) · Biological Chemistry · doi:10.1515/hsz-2020-0345 · Cited by 10
The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia
Li, Q., Wang, M., & Liu, L. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115539 · Cited by 11
Aberrant expression of T cell activation markers and upregulation of Tregs in bone marrow and peripheral blood in acute myeloid leukemia patients
Fang, J., Zhang, R., Lin, X., Xu, Y. X., Huang, K., & Saw, P. E. (2023) · Hematology · doi:10.1080/16078454.2023.2219554 · Cited by 10
Integrative spatial multi-omics reveal niche-specific inflammatory signaling and differentiation hierarchies in AML
Dasdemir, E., Veletić, I., Ly, C. P., Quesada, A. E., Pacheco, C. D., Jelloul, F. Z., Borges, P., Basu, S., Jindal, S., Wang, Z., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114289 · Cited by 9
Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency
Flynn, P., Long, M. D., Kosaka, Y., Long, N., Mulkey, J. S., Coy, J. L., Agarwal, A., & Lind, E. F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1297338 · Cited by 8
Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia
Sobash, P. T., Kolhe, R. B., Karim, N. A., Guddati, A. K., Jillella, A., & Kota, V. K. (2020) · Future Oncology · doi:10.2217/fon-2019-0642 · Cited by 8
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia
Hutchings, M., Korfi, K., Montesinos, P., Santoro, A., Hou, H., Martínez‐Sánchez, P., Vives, S., Galimberti, S., Chen, T., Frigeni, M., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100110 · Cited by 7
Recent advances in drug delivery and treatment strategies for acute myeloid leukemia
Pan, Q., & Mahato, R. I. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126078 · Cited by 7
FLT3LG and IFITM3P6 consolidate T cell activity in the bone marrow microenvironment and are prognostic factors in acute myelocytic leukemia
Chen, H., Wu, M., Xia, H., Du, S., Zhou, G., Long, G., Zhu, Y., Huang, X., & Yang, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980911 · Cited by 7
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML ‐001 trial
Menezes, D. L. D., See, W. L., Risueño, A., Tsai, K.-T., Lee, J. K., Ma, J., Khan, R., Prébet, T., Skikne, B., Beach, C. L., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18783 · Cited by 7
Toll-like receptor 9 negatively related to clinical outcome of AML patients
Al-Kahiry, W., Dammag, E. A. M., Abdelsalam, H. S. T., Fadlallah, H. K., & Owais, M. S. (2020) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-020-00027-3 · Cited by 7
Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes
Zhu, J., Huang, X., Fu, Y., Wang, Y., Zheng, P., Liu, Y., & Han, Z. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048953 · Cited by 6
Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial
Kiguchi, T., Yamaguchi, M., Takezako, N., Miyawaki, S., Masui, K., Ihara, Y., Hirota, M., Shimofurutani, N., & Naoe, T. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03074-4 · Cited by 6
m5C regulator‐mediated methylation modification patterns and tumor microenvironment infiltration characteristics in acute myeloid leukemia
Wen, Q. J., Wang, S., Hong, L., Shen, S., He, Y., Sheng, X., Zhuang, X., Chen, S., Wang, Y., & Zhuang, H. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1150 · Cited by 6
Characterization of somatic mutation-associated microenvironment signatures in acute myeloid leukemia patients based on TCGA analysis
Wang, J., Dao, F., Yang, L., & Qin, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-76048-8 · Cited by 6
Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status
Jiao, X., Zhou, J., Liang, X., Zhu, J., Xiao, M., Ding, Y., Tao, Q., Xiao, H., Li, Y., Wang, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-01600-3 · Cited by 5
Mechanisms of T‑cell metabolic reprogramming in the microenvironment of acute myeloid leukemia and its therapeutic potential (Review)
Luo, Y., Luo, J., Yang, M. J., & Zhao, X. (2025) · Oncology Letters · doi:10.3892/ol.2025.15201 · Cited by 5
Immune‐dysregulation harnessing in myeloid neoplasms
Sharifi, M. J., Xu, L., Nasiri, N., Ashja‐Arvan, M., Soleimanzadeh, H., & Ganjalıkhani-Hakemi, M. (2024) · Cancer Medicine · doi:10.1002/cam4.70152 · Cited by 5
CD8 + T‐cell percentage increases in diffuse large B‐cell lymphoma patients receiving mannatide combined with standard regimens
Wang, M., Wang, B., & Fang, W. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13370 · Cited by 4
Opportunities for immunotherapy in childhood acute myeloid leukemia
Lamble, A. J., & Tasian, S. K. (2019) · Hematology · doi:10.1182/hematology.2019000357 · Cited by 4
Visfatin promotes the malignancy of human acute myeloid leukemia cells via regulation of IL-17
Hui, Z., Liu, Z., He, A., Chen, Y., Zhang, P., Lei, B., Yao, H., Yu, Y., Liang, R., Li, Z., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.03.016 · Cited by 4
A Systems Biology- and Machine Learning-Based Study to Unravel Potential Therapeutic Mechanisms of Midostaurin as a Multitarget Therapy on FLT3-Mutated AML
Díaz‐Beyá, M., García‐Fortes, M., Valls, R., Artigas, L., Gómez-Casares, M. ª. T., Montesinos, P., Sanchez-Guijo, F. M., Coma, M., Vendranes, M., & Martínez‐López, J. (2022) · BioMedInformatics · doi:10.3390/biomedinformatics2030024 · Cited by 3
DOGMA-seq and multimodal, single-cell analysis in acute myeloid leukemia
Kim, J., Schanzer, N., Singh, R. S., Zaman, M. I., Medina, J. S. G., Proszynski, J., Ganesan, S., Landau, D. A., Park, C. Y., Melnick, A. M., et al. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.08.001 · Cited by 3
Characteristics of Pyroptosis-Related Subtypes and Novel Scoring Tool for the Prognosis and Chemotherapy Response in Acute Myeloid Leukemia
Pan, J., Jiang, Y., Li, C., Jin, T., Yu, K., & Jin, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.898236 · Cited by 3
Ubiquitin-specific protease 34 serves as a novel prognostic biomarker through correlating with immune responses and cell proliferation in acute myeloid leukemia
Li, Z., & Shi, C. (2025) · Discover Oncology · doi:10.1007/s12672-025-03662-1 · Cited by 2
Elucidating the Role of the T Cell Receptor Repertoire in Myelodysplastic Neoplasms and Acute Myeloid Leukemia
Barakos, G. P., Georgoulis, V., Koumpis, E., & Hatzimichael, E. C. (2025) · Diseases · doi:10.3390/diseases13010019 · Cited by 2
Effect of Age, Sex and Season on Acute Myeloid Leukemia Clinical Characteristics: A Retrospective Study
Wan, X., Tao, T., Zhang, J., Li, N., Gou, Y., Yang, W., Han, X., Wu, S., Zhang, C., Peng, X., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s495615 · Cited by 2
UBTF facilitates acute myeloid leukemia development and immune escape via PD-L1 regulation
Yang, C., Wan, J., Wang, Y., Yang, Y., Ran, Y., Zhang, F., Zhou, M., Liu, P., Kang, Q., Ma, D., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114433 · Cited by 2
Genetic variant within CDK6 regulates immune response to palbociclib treatment
Serra, V., Orrù, V., Steri, M., Fiorillo, E., Cucca, F., & Żołędziewska, M. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108777 · Cited by 2
Expression of immune checkpoint molecules in Iraqi acute myeloid leukemia patients
Al-Hashemi, H. S., Rahman, S. A. H. A., & Shabeeb, Z. (2021) · Iraqi Journal of Hematology · doi:10.4103/ijh.ijh_46_20 · Cited by 4
The Role of Immune Check Point Gene Expression of Pd-1 and Tim-3 in Patients with Acute Myeloid Leukemia
Oudah, S. M., Hamzah, I. H., Matti, B. F., & Alkasir, R. (2024) · Al-Mustansiriyah Journal of Sciences · doi:10.23851/mjs.v35i1.1418 · Cited by 2

Authors: Lamble, A. J., & Lind, E. F.
Affiliations: Seattle Children's Hospital (US)
Oregon Health & Science University (US)
Corresponding author: Lind, Evan F.
ORCID: Lamble, Adam J.
Lind, Evan F.
Venue: Frontiers in Oncology
Publisher: Frontiers Media SA
Published: 2018-06-13
Volume: 8
Pages: 213-213
ISSN: 2234-943X (ISSN-L)
DOI: 10.3389/fonc.2018.00213
PMC: PMC6008423
OpenAlex: W2807706866
Cited by: 119
References: 145
Citations by year: 2026: 5 · 2025: 13 · 2024: 12 · 2023: 14 · 2022: 12 · 2021: 29 · 2020: 19 · 2019: 15
FWCI: 2.59
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: Frontiers in Oncology (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Cancer Center (U54CA224019, U01CA217862)
Leukemia and Lymphoma Society
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: acute myeloid leukemia, tumor immune microenvironment, T cell immunity, immune checkpoint, immunotherapy, chimeric antigen receptor T cells, bispecific antibodies, immune checkpoint inhibitors, allogeneic bone marrow transplantation, treatment resistance, recurrence, predictive biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks